This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ArthroCare Reports Third Quarter 2011 Financial Results

BALANCE SHEET AND CASH FLOWS

Cash and cash equivalents increased $75.1 million to $207.7 million as of September 30, 2011 from December 31, 2010. Cash flows provided by operating activities for the nine months ended September 30, 2011 was $69.8 million compared to $63.6 million for the nine months ended September 30, 2010.

CONFERENCE CALL

ArthroCare will hold a conference call with the financial community to present these results at 8:30 a.m. ET/5:30 a.m. PT on Thursday, November 3, 2011. To participate in the live conference call dial 800-950-3502. A live and on-demand webcast of the call will be available on ArthroCare’s Web site at www.arthrocare.com. A telephonic replay of the conference call can be accessed by dialing 800-633-8284 and entering pass code number 21544090. The replay will remain available through November 17, 2011.

ABOUT ARTHROCARE

ArthroCare develops and manufactures surgical devices, instruments, and implants that strive to enhance surgical techniques as well as improve patient outcomes. Its devices improve many existing surgical procedures and enable new minimally invasive procedures. Many of ArthroCare’s devices use its internationally patented Coblation ® technology. This technology precisely dissolves target tissue and limits damage to surrounding healthy tissue. ArthroCare also develops surgical devices utilizing other patented technology including its OPUS ® line of fixation products as well as re-usable surgical instruments. ArthroCare is leveraging these technologies in order to offer a comprehensive line of surgical devices to capitalize on a multi-billion dollar market opportunity across several surgical specialties, including its two core product areas consisting of Sports Medicine and Ear, Nose, and Throat as well as other areas such as spine, wound care, urology and gynecology.

FORWARD-LOOKING STATEMENTS

The information provided herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on beliefs and assumptions by management and on information currently available to management. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Additional factors that could cause actual results to differ materially from those contained in any forward-looking statement include, without limitation: the resolution of litigation pending against the Company; the Company’s ability to design or improve internal controls to address issues detected in its reviews of internal controls and insurance reimbursement practices or by management in its reassessment of the Company’s internal controls; the impact upon the Company’s operations of legal compliance matters or internal controls review, improvement and remediation; the ability of the Company to control expenses relating to legal compliance matters or internal controls review, improvement and remediation; the Company’s ability to remain current in its periodic reporting requirements under the Exchange Act and to file required reports with the Securities and Exchange Commission on a timely basis; the results of the investigation being conducted by the United States Department of Justice; the impact on the Company of additional civil and criminal investigations by state and federal agencies and civil suits by private third parties involving the Company’s financial reporting and its previously announced restatement and its insurance billing and healthcare fraud-and-abuse compliance practices; the ability of the Company to attract and retain qualified senior management and to prepare and implement appropriate succession planning for its Chief Executive Officer; general business, economic and political conditions; competitive developments in the medical devices market; changes in applicable legislative or regulatory requirements; the Company’s ability to effectively and successfully implement its financial and strategic alternatives, as well as business strategies, and manage the risks in its business; and the reactions of the marketplace to the foregoing.

 
ARTHROCARE CORPORATION
Condensed Consolidated Balance Sheets - Unaudited
(in thousands, except par value data)
    September 30, 2011   December 31, 2010
 
ASSETS
Current assets:
Cash and cash equivalents $ 207,674 $ 132,536

Accounts receivable, net of allowances of $2,226 and $2,445 at September 30, 2011 and December 31, 2010, respectively

39,917 48,870
Inventories, net 35,593 34,087
Deferred tax assets 18,496 24,661
Prepaid expenses and other current assets 5,929 4,424
Assets held for sale   -     3,081  
Total current assets 307,609 247,659
 
Property and equipment, net 36,120 41,582
Intangible assets, net 6,770 10,733
Goodwill 119,154 119,020
Deferred tax assets 16,019 16,019
Other assets   1,617     4,182  
Total assets $ 487,289   $ 439,195  
 

LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable $ 15,223 $ 13,819
Accrued liabilities 45,751 40,197
Deferred tax liabilities 149 149
Income tax payable   2,071     1,555  
Total current liabilities 63,194 55,720
 
Deferred tax liabilities 213 213
Other non-current liabilities   14,174     13,766  
Total liabilities 77,581 69,699
 

Series A 3% Redeemable Convertible Preferred Stock, par value $0.001; Authorized: 100 shares; Issued and outstanding: 75 shares at September 30, 2011 and December 31, 2010; Redemption value $87,089

76,316 73,768
 
Stockholders' equity:
Preferred stock, par value $0.001; Authorized: 4,900 shares; Issued and outstanding: none - -

Common stock, par value $0.001; Authorized: 75,000 shares; Issued: 31,458 and 31,102 shares; Outstanding: 27,479 and 27,112 shares at September 30, 2011 and December 31, 2010, respectively

27 27

Treasury stock: 3,978 shares at September 30, 2011 and 3,990 shares December 31, 2010

(107,408 ) (107,899 )
Additional paid-in capital 398,270 386,395
Accumulated other comprehensive income 4,611 4,246
Retained earnings   37,892     12,959  
Total stockholders' equity   333,392     295,728  
Total liabilities, redeemable convertible preferred stock and stockholders' equity $ 487,289   $ 439,195  
 
 
ARTHROCARE CORPORATION
Condensed Consolidated Statements of Operations - Unaudited
(in thousands, except per share data)
    Three Months Ended

September 30,

  Nine Months Ended

September 30,

2011   2010 2011   2010
 
Revenues:
Product sales $ 79,432 $ 82,917 $ 249,864 $ 251,148
Royalties, fees and other   3,835     3,536     12,609     11,598  
Total revenues 83,267 86,453 262,473 262,746
 
Cost of product sales   25,529     28,632     76,170     83,569  
 
Gross profit   57,738     57,821     186,303     179,177  
Operating expenses:
Research and development 8,037 9,244 21,460 26,537
Sales and marketing 25,752 26,156 81,124 79,898
General and administrative 9,479 9,723 26,372 26,048
Amortization of intangible assets 1,338 1,315 3,972 3,932
Exit costs 2,814 - 5,304 -
Investigation and restatement related costs   5,963     (99 )   12,145     3,245  
Total operating expenses   53,383     46,339     150,377     139,660  
 
Income from operations 4,355 11,482 35,926 39,517
Foreign exchange gain (loss) (902 ) 1,323 (160 ) (2,711 )
Interest and other expense, net   (126 )   (96 )   (501 )   (287 )
Other income (expense)   (1,028 )   1,227     (661 )   (2,998 )
 
Income from continuing operations before income taxes 3,327 12,709 35,265 36,519
 
Income tax provision   898     3,536     9,677     9,984  
 
Net income from continuing operations 2,429 9,173 25,588 26,535
 
Income (loss) from discontinued operations   -     85     1,911     (368 )
 
Net income 2,429 9,258 27,499 26,167
 

Accrued dividend and accretion charges on Series A 3% Convertible Preferred Stock

  (857 )   (820 )   (2,546 )   (2,434 )
 
Net income available to common stockholders $ 1,572   $ 8,438   $ 24,953   $ 23,733  
 

Weighted-average shares outstanding:

Basic 27,466 27,017 27,335 26,972
Diluted 27,855 27,323 27,755 27,299
 
Earnings per share from continuing operations applicable to common stockholders:
Basic $ 0.05   $ 0.25   $ 0.70   $ 0.74  
Diluted $ 0.05   $ 0.25   $ 0.68   $ 0.73  
 
 

Earnings per share applicable to common stockholders:

Basic $ 0.05   $ 0.26   $ 0.75   $ 0.72  
Diluted $ 0.05   $ 0.25   $ 0.74   $ 0.72  
 
 
ARTHROCARE CORPORATION
Supplemental Schedule of Product Sales
(in thousands)
 
    Three Months Ended   Three Months Ended
September 30, 2011 September 30, 2010
Americas   International   Total Product Sales   % Net Product Sales   Americas   International   Total Product Sales   % Net Product Sales
         
 
Sports Medicine $ 33,251 $ 18,850 $ 52,101 65.6 % $

40,029

$ 16,944 $

56,973

68.7

%
ENT 20,046 4,851 24,897 31.3 %

19,379

3,636

23,015

27.8

%
Other   658   1,776   2,434 3.1 %   1,016   1,913   2,929 3.5 %
Total Product Sales $ 53,955 $ 25,477 $ 79,432 100.0 % $ 60,424 $ 22,493 $ 82,917 100.0 %
 
 
 
Nine Months Ended Nine Months Ended
September 30, 2011 September 30, 2010
Americas   International   Total Product Sales   % Net Product Sales   Americas International   Total Product Sales   % Net Product Sales
 
 
Sports Medicine $ 106,980 $ 58,987 $ 165,967 66.4 % $

122,121

$ 50,012 $

172,133

68.5 %
ENT 62,732 13,903 76,635 30.7 %

58,990

10,945

69,935

27.9 %
Other   2,203   5,059   7,262 2.9 %  

3,115

  5,965  

9,080

3.6 %
Total Product Sales $ 171,915 $ 77,949 $ 249,864 100.0 % $ 184,226 $ 66,922 $ 251,148 100.0 %




3 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs